Information Provided By:
Fly News Breaks for November 18, 2015
BLUE
Nov 18, 2015 | 06:24 EDT
Goldman Sachs analyst Salveen Richter started bluebird bio with a Buy rating and $165 price target. bluebird is the leading gene therapy play and the 62% pullback in shares since the July highs provides an attractive entry point, Richter tells investors in a research note.